Tirzepatide 5mg

Tirzepatide represents a revolutionary breakthrough as the first GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 dual receptor agonist. This synthetic 39-amino acid peptide (MW: 4813 Da) integrates:

Molecular Architecture:

• Human native GIP sequence (amino acids 1-30)
• Modification Wing²: substitution with 2-aminoisobutyric acid (DPP-4 stability)
• C20 acyl side chain at Lys²⁰ with gamma-Glu-OEG spacer
• Albumin binding: >99% (extended half-life)

Synergistic Dual Mechanisms

Via GIP (GIP Receptor-R):

• Predominant expression: pancreatic β-cells, adipocytes, brain
• Enhanced insulin secretion: 50-70% is superior to GLP-1 alone
• Adipocyte lipolysis: cAMP/PKA pathway activation
• Neuroprotection: expression in hippocampus and cortex

Via GLP-1 (GLP-1R Receptor):

• Glucose-dependent insulin secretion
• Central appetite suppression (arcuate/paraventricular nucleus)
• Delayed gastric emptying (70-80%)
• Glucagon secretion inhibition

Distinctive Pharmacokinetics:

• SC Bioavailability: 80%
• Tmáx: 8-72 hours (broad peak)
• Average lifespan: ~5 days (120 hours)
• Steady state: 4 weeks
• Elimination: proteolytic degradation + minimal renal excretion

Metabolic Superiority in Comparative Studies

SURPASS Studies (vs. Semaglutide):

• HbA1c reduction: 2.4% vs. 1.9% with semaglutide (Frias et al., 2021)
• Weight loss: 15.7kg vs 12.4kg with semaglutide 1mg (maximum doses)
• Patients achieving HbA1c <5.7%: 51% vs. 20%

Advanced Body Recomposition:

• Visceral fat loss: 40–45% (greater than subcutaneous fat)
• Muscle mass preservation: 92–95% of the loss is adipose tissue
• Improves liver composition: reduces hepatic fat (NASH)

Cardiovascular and Metabolic Effects

Cardiometabolic Biomarkers

• Blood pressure reduction: 7-10 mmHg systolic
• Lipid profile: ↓ triglycerides 25%, ↑ HDL 8-12%
• Serum adiponectin: increase 35–50%
• Inflammatory markers: Reduced CRP 40%

Endothelial Function

• Improves endothelium-dependent vasodilation: 25-30%
• Reduction of oxidative stress: decrease in ROS 40%
• eNOS Expression: 50% Increase in Vascular Models

Neuroscience and Cognitive Function

Dual Neuroprotection (GIP + GLP-1)

• Reduction of cerebral β-amyloid: 45% in Alzheimer's disease models (Cai et al., 2022)
• Prevention of Synaptic Loss: 60% vs. Controls
• Hippocampal neurogenesis: 55% increase (greater than GLP-1 alone)
• Improves spatial memory: 40% in Morris Water Maze tests

Stepped Dosing (Preclinical Models)

In Vitro Applications

Cellular Systems

• Pancreatic islets: 1-10 nM (insulin secretion study)
• Differentiated adipocytes: 5-50 nM (lipolysis, glucose uptake)
• Cortical neurons: 10–100 nM (neuroprotection, plasticity)
• Primary hepatocytes: 10-25 nM (lipid metabolism)

Detailed Procedure:

1. Sterile environment: laminar flow hood or clean room
2. Bacteriostatic water (0.9% benzyl alcohol), pH 7–7.4
3. Vial 5mg: add 2.0mL → 2.5mg/mL
4. Vial 10mg: add 4.0mL → 2.5mg/mL
5. Slow injection sidewall (minimize turbulence)
6. Smooth circular rotation 45-60 seconds
7. Visual inspection: clear solution with no precipitate

Storage Conditions

• Before reconstitution: -20°C for up to 24 months
• After reconstitution: 2-8°C for up to 21 days
• Do not freeze reconstituted solution
• Amber vials or aluminum protection (photosensitivity)

Why does tirzepatide outperform single GLP-1 agonists? A: Dual GIP/GLP-1 activation produces a synergistic effect: GIP enhances insulin secretion and lipolysis, while GLP-1 maximizes satiety and glycemic control, resulting in 30-40% superior effects.

A: ¿Es apropiado para modelos de enfermedad hepática grasa? A: Excellent for NAFLD/NASH: reduces steatosis (50%), improves ALT/AST levels (35%), and reduces hepatic fibrosis as determined by histology (Hartman et al., 2020).

Optimal protocol for body composition studies? A: DEXA or baseline MRI and at weeks 4, 8, 12, and 16; abdominal circumference measurements every two weeks; plasma metabolomic analysis every 4 weeks.

P: Interactions with basal insulin research? A: Compatible and synergistic; it allows for a reduction in insulin dosage by 40-50% while maintaining glycemic control, with fewer episodes of hypoglycemia.

1. Frias JP, et al. (2021) “Tirzepatide Versus Semaglutide Once Weekly in Patients With Type 2 Diabetes” – The New England Journal of Medicine 385(6):503-515. [PubMed: 34170647]
2. Rosenstock J, et al. (2021) “Efficacy and safety of once-weekly tirzepatide” – Lancet 398(10295):143-155. [PubMed: 34186022]
3. Cai HY, et al. (2022) “Dual GIP/GLP-1 receptor agonist in Alzheimer’s disease models” – Neuropharmacology210:109023. [PubMed: 35364126]
4. Hartman ML, et al. (2020) “Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis” – Hepatology 71(4):1222-1232. [PubMed: 31625611]
5. Eli Lilly Research (2022) “Tirzepatide: A novel dual GIP and GLP-1 receptor agonist” – Cell Metabolism 33(7):1284-1295.

This browser does not support iframes. You can download the PDF here:
Download PDF.

This browser does not support iframes. You can download the PDF here:
Download PDF.